Disease/Infection News

RSS

Pharmasset commences combination study of PSI-7977 and PSI-938 nucleotide analogs in HCV

Pharmasset, Inc. announced today that dosing has begun in Part 2 of a Phase 1 study. This is the first clinical study combining a purine (PSI-938) and a pyrimidine (PSI-7977) nucleotide analog for HCV, and is designed to evaluate once daily doses of PSI-7977 and PSI-938 in patients with HCV who have not been treated previously.

30 Nov 2010

AIDS Healthcare Foundation to participate in Members Project

AIDS Healthcare Foundation (AHF) is proud to be selected as a candidate charity in Members Project, a partnership between American Express and TakePart.

30 Nov 2010

Emergency artesunate suppositories are cost-effective intervention for children with suspected severe malaria

Giving emergency artesunate suppositories to children with suspected severe malaria before referring them for treatment is a cost-effective intervention that can substantially improve the management of childhood malaria in remote African settings, according to a new study led by Boston University School of Public Health [BUSPH] researcher Yesim Tozan, PhD.

30 Nov 2010

American Red Cross announces additional $2 million to combat cholera epidemic in Haiti

The American Red Cross announced today it is committing an additional $2 million to combat an escalating cholera epidemic in Haiti that has killed more than 1,700 people and sickened more than 75,000.

30 Nov 2010

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway.

30 Nov 2010

New study may lead to non-medicinal methods of eradicating Hamburger disease

Hamburger disease, a debilitating form of food poisoning, may be a thing of the past. New findings from an international research collaboration conducted by the French National Institute for Agronomic Research (INRA), involving the Universit- de Montr-al are the first to show how the contaminating E.coli bacterium is able to survive in the competitive environment of a cow's intestine by scavenging specific food sources.

30 Nov 2010

International Harm Reduction Conference to focus on HIV/AIDS epidemic

Injecting drug use and growing HIV/AIDS epidemic in Middle East and North Africa region to be focus of the International Harm Reduction conference taking place in Beirut, Lebanon April 3-7 2011

30 Nov 2010

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.

30 Nov 2010

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

A study by researchers in the Royal College of Surgeons in Ireland (RCSI) has uncovered a potential new target for the treatment of a range of intestinal diseases that are associated with diarrhoea. Current medications are often ineffective and can have serious side effects so this discovery gives hope for the development of new treatments for sufferers of intestinal disease.

30 Nov 2010

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

30 Nov 2010

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

A team of scientists from The Scripps Research Institute have uncovered a previously unknown regulatory mechanism in the body's response to eliminate pathogens, such as bacteria and viruses. The findings challenge a long-held dogma in the field of immunology and have potential implications for far-ranging topics from how vaccines should be administered to the origin of autoimmunity.

30 Nov 2010

University of Adelaide researcher leads collaboration for universal flu vaccine

A University of Adelaide researcher is leading a collaboration between Australia and Indonesia on the production of a universal flu vaccine. The frequent arising of new influenza strains represents the greatest challenge to health authorities as it renders currently available vaccines ineffective, says Dr Mohammed Alsharifi, the Head of the Vaccine Research Group at the School of Molecular and Biomedical Science, University of Adelaide.

30 Nov 2010

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Haiti requires additional trained nurses, doctors to address cholera epidemic, U.N. official says

Haiti needs about 1,000 additional trained nurses and at least 100 more physicians to control the cholera epidemic, Valerie Amos, the U.N. undersecretary-general for humanitarian affairs, said during a recent visit to the capital of Port-au-Prince, Reuters reports.

30 Nov 2010

To reduce spread of HIV/AIDS, IFRC calls for more focus on IDU programs

Ahead of World AIDS Day, the International Federation of the Red Cross on Friday released a report (.pdf) calling for governments around the world to do more to help stop the spread of HIV/AIDS among populations of injecting drug users (IDUs), the Associated Press reports (Heilprin, 11/25).

30 Nov 2010

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck today reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naïve adult patients infected with HIV-1. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults.

29 Nov 2010

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.

29 Nov 2010

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

QIAGEN has been selected to contribute to the fight against infectious diseases in animals in emerging countries by supplying an international pilot project associated with the United Nations with portable devices to perform ultra-fast molecular testing in the field.

From QIAGEN Manchester Limited 29 Nov 2010

New laboratory test for pregnant women to detect GBS infections

A more rapid laboratory test for pregnant women to detect Group B strep (GBS), the most common cause of life-threatening infections in newborns, is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth).

29 Nov 2010

Overexposure to triclosan may negatively influence immune system: Study

Young people who are overexposed to antibacterial soaps containing triclosan may suffer more allergies, and exposure to higher levels of Bisphenol A among adults may negatively influence the immune system, a new University of Michigan School of Public Health study suggests.

29 Nov 2010

Disease/Infection News

Pharmasset commences combination study of PSI-7977 and PSI-938 nucleotide analogs in HCV

AIDS Healthcare Foundation to participate in Members Project

Emergency artesunate suppositories are cost-effective intervention for children with suspected severe malaria

American Red Cross announces additional $2 million to combat cholera epidemic in Haiti

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

New study may lead to non-medicinal methods of eradicating Hamburger disease

International Harm Reduction Conference to focus on HIV/AIDS epidemic

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

University of Adelaide researcher leads collaboration for universal flu vaccine

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Haiti requires additional trained nurses, doctors to address cholera epidemic, U.N. official says

To reduce spread of HIV/AIDS, IFRC calls for more focus on IDU programs

Merck announces initial results from ISENTRESS Phase III study in HIV-1

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

New laboratory test for pregnant women to detect GBS infections

Overexposure to triclosan may negatively influence immune system: Study

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News